DexCom Inc.'s February alert about alarm problems with its G4 Platinum and G5 Mobile continuous glucose monitors for diabetics has been tagged as a class I recall, FDA said
April 11
Dexcom CGM Alarm Issue Tagged As Class I Recall
FDA has labeled a DexCom alert about alarm activation failures with its G4 Platinum and G5 Mobile continuous glucose monitoring systems as a class I recall.
More from Recalls
More from Policy & Regulation
• By
In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.
• By
The World Health Organization is seeking input from stakeholders to create an official definition of the term ‘diagnostics.’ This initiative follows a 2023 resolution aimed at enhancing global diagnostics capacity; the definition, it is hoped, will help drive the creation of effective health policies. Comments will be accepted until 23 May.
• By
HHS Secretary Robert F. Kennedy, Jr. is asking the public to help cut waste across the government’s health agencies. Kennedy announced a 60-day comment period allowing the public to take part in a broader federal initiative to reduce regulations and increase transparency.